⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 3, 2024Open Access

Supplementary Figure S9 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids

Kanve N. Suvilesh Yariswamy Manjunath Yulia I. Nussbaum Mohamed Gadelkarim Murugesan Raju Akhil Srivastava Guangfu Li Wesley C. Warren Chi‐Ren Shyu Feng Gao Matthew A. Ciorba Jonathan B. Mitchem Satyanarayana Rachagani Jussuf T. Kaifi

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S9. Dose titration of epalrestat against PDTOs to determine the cytotoxicity.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Suvilesh et al. (2024) studied this question.

synapsesocial.com/papers/68e598e8b6db643587533bb4 https://doi.org/10.1158/1078-0432.26926648

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S9 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024
2Supplementary Figure S7 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024
3Supplementary Figure S7 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024
4Supplementary Figure S8 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024
5Supplementary Figure S8 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024

Supplementary Figure S10 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024
Supplementary Figure S10 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024
Supplementary Figure S1 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids2024